Methylacridinium and its cholinergic properties

Neurotoxicity Research

Volumn 16, Issue 4, 2009, Pages 372-377

  Soukup, Ondrej ^a   Proska, Jan ^b   Binder, Jiri ^c   Karasova, Jana Zdarova ^a   Tobin, Gunnar ^d   Jun, Daniel ^a   Marek, Jan ^a   Musílek, Kamil ^a   Fusek, Josef ^a   Kuca, Kamil ^a,e  

^a UNIVERSITY OF DEFENCE   (Czech Republic)

^b CZECH TECHNICAL UNIVERSITY IN PRAGUE   (Czech Republic)

^c Charles University in Prague Faculty of Pharmacy   (Czech Republic)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e J E PURKINJE UNIVERSITY   (Czech Republic)

Author keywords

Alzheimer's disease; Blood brain barrier; Cholinesterase; Contractile studies; Methylacridinium; Muscarinic receptor

Indexed keywords

10 METHYLACRIDINIUM IODIDE; ACETYLCHOLINESTERASE; CHOLINESTERASE; ENZYME INHIBITOR; METHYLSCOPOLAMINE; MUSCARINIC M2 RECEPTOR; UNCLASSIFIED DRUG; 10 METHYLACRIDINE; ACRIDINE DERIVATIVE; CHOLINERGIC RECEPTOR STIMULATING AGENT; N-METHYLACRIDINE;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BLADDER; BLOOD BRAIN BARRIER; CHOLINERGIC SYSTEM; CONTROLLED STUDY; DRUG MECHANISM; DRUG SCREENING; DRUG STRUCTURE; ENZYME INHIBITION; IC 50; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BINDING; SPECTROPHOTOMETRY; SWINE; ANIMAL; BINDING SITE; BLOOD; CHEMICAL MODEL; CHEMISTRY; COMPUTER SIMULATION; DOSE RESPONSE; DRUG EFFECT; ENZYME SPECIFICITY; HEART; HUMAN; METABOLISM; MOUSE; PHYSIOLOGY; PROTEIN BINDING; REGRESSION ANALYSIS; SERUM; SPRAGUE DAWLEY RAT;

RATTUS;

ACETYLCHOLINESTERASE; ACRIDINES; ANIMALS; BINDING SITES; BLOOD-BRAIN BARRIER; BUTYRYLCHOLINESTERASE; CHOLINERGIC AGENTS; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART; HUMANS; INHIBITORY CONCENTRATION 50; MICE; MODELS, CHEMICAL; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; REGRESSION ANALYSIS; SERUM; SUBSTRATE SPECIFICITY; SWINE; URINARY BLADDER;

EID: 74949109750     PISSN: 10298428     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12640-009-9071-8     Document Type: Article

References (21)

1. Abrams P, Andersson KE, Buccafusco JJ, Chapple C, de Groat WC, Fryer AD et al (2006) Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 148:565-578
2. Bajgar J (2004) Organophosphates/nerve agent poisoning: mechanism of action, diagnosis, prophylaxis, and treatment. Adv Clin Chem 38:151-216
3. Ellman GL, Courtney KD, Andres V, Featherstone RM (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7:88
4. Fisher A (2008) M1 muscarinic agonists target major hallmarks of Alzheimer's disease the pivotal role of brain M1 receptors. Neurodegener Dis 5:237-240
5. Garcia-Carrasco M, Escarcega RO, Fuentes-Alexandro S, Riebeling C, Cervera R (2007) Therapeutic options in autoimmune myasthenia gravis. Autoimmun Rev 6:373-378
6. Giacobini E, Holmsted B (1958) Cholinesterase content of certain regions of spinal cord as judged by histochemical and Cartesian driver technique. Acta Physiol Scand 1:2-27
7. Giglio D, Aronsson P, Eriksson L, Tobin G (2007) In vitro characterization of parasympathetic and sympathetic responses in cyclophosphamide-induced cystitis in the rat. Basic Clin Pharmacol Toxicol 100:96-108
8. Holzgrabe U, Kapkova P, Alptuzun V, Scheiber J, Kugelmann E (2007) Targeting acetylcholinesterase to treat neurodegeneration. Expert Opin Ther Targets 11:161-179
9. Johnson JL, Cusack B, Hughes TF, McCullough EH, Fauq A, Romanovskis P et al (2003) Inhibitors tethered near the acetylcholinesterase active site serve as molecular rulers of the peripheral and acylation sites. J Biol Chem 278:38948-38955
10. Kuca K, Cabal J, Patocka J, Dohnal V (2004) Quaternary heteroarenium salts as the competitive inhibitors of the brain acetylcholinesterase. Lett Drug Des Discov 1:35-44
11. Loke WK, Sim MK, Go ML (2002) O-Substituted derivatives of pralidoxime: muscarinic properties and protection against soman effects in rats. Eur J Pharmacol 442:279-287
12. Musilkova J, Tucek S (1991) The binding of cholinesterase-inhibitors tacrine (Terahydroaminoacridine) and 7-methoxytacrine to muscarinic acetylcholine-receptors in rat-brain in the presence of eserine. Neurosci Lett 125:113-116
13. Ogura H, Kosasa T, Kuriya Y, Yamanishi Y (2000) Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro. Methods Find Exp Clin Pharmacol 22:609-613
14. Parihar MS, Hemnani T (2004) Alzheimer's disease pathogenesis and therapeutic interventions. J Clin Neurosci 11:456-467
15. Radic Z, Taylor P (2006) Structure and function of cholinesterases. In: Gupta R (ed) Toxicology of organophospate, carbamate compounds. Elsevier Academic Press, London, pp 161-186
16. Sakurada K, Matsubara K, Shimizu K, Shiono H, Seto Y, Tsuge K et al (2003) Pralidoxime iodide (2-PAM) penetrates across the blood-brain barrier. Neurochem Res 28:1401-1407
17. Soukup O, Pohanka M, Tobin G, Jun D, Fusek J, Musilek K et al (2008) The effect of HI-6 on cholinesterases and on the cholinergic system of the rat bladder. Neuro Endocrinol Lett 29:759-762
18. Sussman JL, Harel M, Frolow F, Oefner C, Goldman A, Toker L et al (1991) Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein. Science 253:872-879
19. Trankle C, Dittmann A, Schulz U, Weyand O, Buller S, Johren K et al (2005) Atypical muscarinic allosteric modulation: cooperativity between modulators and their atypical binding topology in muscarinic M2 and M2/M5 chimeric receptors. Mol Pharmacol 68:1597-1610
20. van Helden HP, Busker RW, Melchers BP, Bruijnzeel PL (1996) Pharmacological effects of oximes: how relevant are they? Arch Toxicol 70:779-786
21. Zapletalek M, Hanus H, Fusek J, Hrdina V (1989) First experience with the application of 7-methoxytacrine to psychiatric patients. Act Nerv Super (Praha) 31:305-306